HIV-2 protease as a chemotherapeutic target

A tétel rövid nézete
dc.contributor.advisorTőzsér, József
dc.contributor.authorMahdi, Mohamed
dc.contributor.departmentMolekuláris sejt- és immunbiológia doktori iskolahu
dc.date.accessioned2016-08-18T08:21:35Z
dc.date.available2016-08-18T08:21:35Z
dc.date.created2016hu_HU
dc.date.defended2016-09-05
dc.description.abstractIn summary, we presented a comprehensive analysis of HIV-2 protease and its susceptibility to the currently marketed PIs. Such data are really scarce, and given the ever increasing incidence of HIV-2 infection, it is wise to characterize the viral responsiveness to combination therapies containing PIs. Having optimized the expression and stability of the viral protease, we can conclude from our comparative enzymatic and cell culture inhibition profiling that lopinavir, darunavir, indinavir sulfate and saquinavir are indeed highly potent HIV-2 protease inhibitors. Tipranavir and nelfinavir on the other hand, showed a significantly lower efficacy when compared to the others. While amprenavir consistently was proven to be a weak inhibitor, the variable results obtained for atazanavir sulfate; enzymatically and in cell culture, incline us to doubt its reliability when used in HIV-2 infected patients. I54M-L90M mutations reduced the susceptibility of the protease to most of the inhibitors to variable degrees, with the exception of tipranavir. Perhaps the use of tipranavir in patients with such identified mutations is advantageous after all. We are confident that the use of such a standardized system capable of carrying out comparative analysis will prove beneficial in tailoring the use of protease inhibitors in HIV-2 infected patients.hu_HU
dc.description.correctorde
dc.format.extent94hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/229850
dc.language.isoenhu_HU
dc.subjectHIVhu_HU
dc.subjectHIV-2
dc.subjectAIDS
dc.subjectantiretroviral therapy
dc.subjectcassette
dc.subjectenzymatic assays
dc.subjectinhibition profiling
dc.subjectprotease
dc.subjectprotease inhibitors
dc.subjectHIV-2 modular system
dc.subjectsusceptibility assays
dc.subject.disciplineElméleti orvostudományokhu
dc.subject.sciencefieldOrvostudományokhu
dc.titleHIV-2 protease as a chemotherapeutic targethu_HU
dc.title.translatedHIV-2 protease as a chemotherapeutic targethu_HU
Fájlok
Eredeti köteg (ORIGINAL bundle)
Megjelenítve 1 - 3 (Összesen 3)
Nem elérhető
Név:
Mohamed_Mahdi_meghivo.pdf
Méret:
388.92 KB
Formátum:
Adobe Portable Document Format
Leírás:
Meghívó-Invitation
Letöltés
Nem elérhető
Név:
Mohamed_Mahdi_short_thesis.pdf
Méret:
826.55 KB
Formátum:
Adobe Portable Document Format
Leírás:
Short_thesis
Letöltés
Nem elérhető
Név:
Mohamed_Mahdi_Thesis_titkositott.pdf
Méret:
2.32 MB
Formátum:
Adobe Portable Document Format
Leírás:
Dissertation
Letöltés
Engedélyek köteg
Megjelenítve 1 - 1 (Összesen 1)
Nem elérhető
Név:
license.txt
Méret:
1.93 KB
Formátum:
Item-specific license agreed upon to submission
Leírás:
Letöltés
Gyűjtemények
Molekuláris Sejt- és Immunbiológia Doktori Iskola